New data for Suliqua®▼ shows improved blood sugar control without weight gain versus premixed insulin in type 2 diabetes
A new study of iGlarLixi met its two primary endpoints and all key secondary endpoints in a head-to-head comparison against premixed insulin (biphasic insulin Aspart 30, BIAsp 30) in adults with type 2 diabetes uncontrolled on insulin and one or two oral anti-diabetic medicines.
The findings were published by Diabetes Care on 28th June, 2021.
The study met both primary endpoints with iGlarLixi demonstrating noninferiority of blood sugar (HbA1c) reduction and superiority on body weight change from baseline compared to premixed insulin. The study also met its key secondary endpoints with iGlarLixi achieving a greater proportion of people reaching a HbA1c target of <7% without weight gain, a greater proportion of people reaching a HbA1c target of <7% without weight gain and without hypoglycaemia (<70mg/dl), and superiority in reduction of HbA1c compared with those using premixed insulin.
Professor Rory McCrimmon, Lead Clinician of the Scottish Diabetes Research Network, said “Concerns about hypoglycaemia and weight gain remain major barriers to patient treatment adherence and ultimately to achieving glycemic control. With this new data which was presented at ADA 2021, we hope to show how adults with type 2 diabetes who are not at their glycemic goal on basal insulin can advancetreatment where needed.”
A secondary descriptive analysis also found study participants using iGlarLixi reported greater improvements in patient-reported outcomes compared to premixed insulin as measured by Treatment-Related Impact Measure Diabetes (TRIM-D) and patient- and physician- rated Global Treatment Effectiveness Evaluation (GTEE) scores. These tools include measurements of treatment burden, daily life, diabetes management, compliance, psychological health, and treatment effectiveness.
Safety findings were in line with the established profiles of iGlarLixi and premixed insulin.
About the SoliMix study
The SoliMix study was a 26-week, randomized controlled trial of 887 adults living with type2 diabetes who were uncontrolled on insulin plus metformin with or without a sodium- glucose cotransporter-2 inhibitor (SGLT-2i). The study compared the efficacy and safety of iGlarLixi compared to a commonly used premixed insulin (BIAsp 30). Participants wererandomized to switch from their prior insulin to either iGlarLixi once daily or premixed insulin twice daily, with starting doses determined and adjusted weekly. Any metformin orSGLT-2i treatment was maintained through the study period.
The study met its two primary endpoints and all three of its key secondary endpoints.
About Suliqua (insulin glargine/lixisenatide)
iGlarLixi, is a once-daily titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide. iGlarLixi is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.1 (Note: The combination is not licensed for weight reduction.)
iGlarLixi is delivered in two pre-filled SoloSTAR® pens, providing different dosing options.1 The differentiation between the pen strengths is based on the dose range and ratios of each pen. 1 The 10–40 SoloSTAR® pre-filled pen will deliver 10 to 40 dose steps of insulin glargine 100 Units/mL in combination with 5 to 20 micrograms of lixisenatide. 1 The 30-60 SoloSTAR pre-filled pen will deliver 30 to 60 dose steps of insulin glargine 100 Units/mL in combination with 10 to 20 micrograms of lixisenatide